These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 20189642)

  • 1. Analysis of placental tissue in Fabry disease with and without enzyme replacement therapy.
    Bouwman MG; Hollak CE; van den Bergh Weerman MA; Wijburg FA; Linthorst GE
    Placenta; 2010 Apr; 31(4):344-6. PubMed ID: 20189642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histologic abnormalities of placental tissues in Fabry disease: a case report and review of the literature.
    Thurberg BL; Politei JM
    Hum Pathol; 2012 Apr; 43(4):610-4. PubMed ID: 22078290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safe and Successful Treatment With Agalsidase Beta During Pregnancy in Fabry Disease.
    Senocak Tasci E; Bicik Z
    Iran J Kidney Dis; 2015 Sep; 9(5):406-8. PubMed ID: 26338166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with agalsidase beta during pregnancy in Fabry disease.
    Politei JM
    J Obstet Gynaecol Res; 2010 Apr; 36(2):428-9. PubMed ID: 20492401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced glucosylceramide in the mouse model of Fabry disease: correction by successful enzyme replacement therapy.
    Quinta R; Rodrigues D; Assunção M; Macedo MF; Azevedo O; Cunha D; Oliveira P; Sá Miranda MC
    Gene; 2014 Feb; 536(1):97-104. PubMed ID: 24334116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Manifestations of Fabry disease in placental tissue.
    Vedder AC; Strijland A; vd Bergh Weerman MA; Florquin S; Aerts JM; Hollak CE
    J Inherit Metab Dis; 2006 Feb; 29(1):106-11. PubMed ID: 16601876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A detailed pathologic examination of heart tissue from three older patients with Anderson-Fabry disease on enzyme replacement therapy.
    Sheppard MN; Cane P; Florio R; Kavantzas N; Close L; Shah J; Lee P; Elliott P
    Cardiovasc Pathol; 2010; 19(5):293-301. PubMed ID: 19631563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful pregnancy outcome in a patient with Fabry disease receiving enzyme replacement therapy with agalsidase alfa.
    Wendt S; Whybra C; Kampmann C; Teichmann E; Beck M
    J Inherit Metab Dis; 2005; 28(5):787-8. PubMed ID: 16151910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uneventful pregnancy outcome after enzyme replacement therapy with agalsidase beta in a heterozygous female with Fabry disease: A case report.
    Germain DP; Bruneval P; Tran TC; Balouet P; Richalet B; Benistan K
    Eur J Med Genet; 2010; 53(2):111-2. PubMed ID: 20045092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical efficacy of enzyme replacement therapy in Fabry disease. A critical review].
    Lidove O; Papo T
    Rev Med Interne; 2009 Oct; 30(10):920-9. PubMed ID: 19524334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fabry disease.
    Thomas AS; Hughes DA
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():88-101. PubMed ID: 25345090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy--a retrospective analysis from the Fabry Outcome Survey.
    Hoffmann B; Beck M; Sunder-Plassmann G; Borsini W; Ricci R; Mehta A;
    Clin J Pain; 2007; 23(6):535-42. PubMed ID: 17575495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fabry disease: focus on cardiac manifestations and molecular mechanisms.
    Perrot A; Osterziel KJ; Beck M; Dietz R; Kampmann C
    Herz; 2002 Nov; 27(7):699-702. PubMed ID: 12439642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzyme replacement therapy in two Japanese siblings with Fabry disease, and its effectiveness on angiokeratoma and neuropathic pain.
    Furujo M; Kubo T; Kobayashi M; Ohashi T
    Mol Genet Metab; 2013 Nov; 110(3):405-10. PubMed ID: 23906479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fabry disease: a treatable lysosomal storage disorder.
    Phadke SR; Mandal K; Girisha KM
    Natl Med J India; 2009; 22(1):20-2. PubMed ID: 19761154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy.
    Banikazemi M; Ullman T; Desnick RJ
    Mol Genet Metab; 2005 Aug; 85(4):255-9. PubMed ID: 15939645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Utility of enzyme replacement therapy in Fabry disease].
    Politei JM; Dubrovsky A
    Med Clin (Barc); 2010 Apr; 134(9):402-5. PubMed ID: 20138313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fabry disease - Vascular manifestations.
    Karetova D; Bultas J; Dostalova G; Palecek T; Kovarnik T; Golan L; Linhart A
    Vasa; 2010 May; 39(2):123-31. PubMed ID: 20464667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A diagnosis of Fabry gastrointestinal disease by chance: a case report.
    Feriozzi S; Torre ES; Ranalli TV; Cardello P; Morrone A; Ancarani E
    Eur J Gastroenterol Hepatol; 2007 Feb; 19(2):163-5. PubMed ID: 17273003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease.
    Lenders M; Brand E
    J Am Soc Nephrol; 2018 Sep; 29(9):2265-2278. PubMed ID: 30093456
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.